Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 6/20 | 0.53 |
| ▸ | GRN | P28799 | 1/20 | 0.52 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 5/20 | 0.51 |
| ▸ | CTSK | P43235 | 9/20 | 0.49 |
| ▸ | CTSS | P25774 | 6/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL212031 | 1.00 | PPARA (0.53) | PPARAGRNSORT1PPARGCTSK | |
| SCHEMBL213064 | 1.00 | PPARA (0.53) | PPARAGRNSORT1PPARGCTSK | |
| SCHEMBL31276763 | 0.94 | PPARA (0.49) | PPARAGRNSORT1PPARGCTSK | |
| SCHEMBL20592494 | 0.88 | PPARA (0.50) | PPARAGRNSORT1PPARGCTSK | |
| SCHEMBL20592496 | 0.88 | PPARA (0.50) | PPARAGRNSORT1PPARGCTSK | |
| SCHEMBL29770564 | 0.88 | PPARA (0.45) | PPARAGRNSORT1PPARGCTSK | |
| SCHEMBL27587953 | 0.87 | GRN (0.54) | PPARAGRNSORT1PPARGCTSK | |
| SCHEMBL27587952 | 0.87 | GRN (0.54) | PPARAGRNSORT1PPARGCTSK | |
| SCHEMBL588912 | 0.86 | PPARA (0.53) | PPARAPPARGCTSKCTSSCTSL | |
| SCHEMBL580779 | 0.86 | PPARA (0.53) | PPARAPPARGCTSKCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113698457-B | Preparation method of gonadorelin acetate | 上海丽珠制药有限公司 | 2024-06-11 | — | — | CN | claimed |
| CN-113698457-A | Preparation method of gonadorelin acetate | 上海丽珠制药有限公司 | 2021-11-26 | — | — | CN | claimed |
| CN-108948147-B | Novel antibiotic for treating drug-resistant gram-positive bacteria and tuberculosis | 清华大学 | 2020-11-17 | — | — | CN | claimed |
| CN-107778352-B | Novel antibiotic for treating drug-resistant gram-positive bacteria and tuberculosis | 清华大学 | 2020-10-27 | — | — | CN | claimed |
| US-12565490-B2 | Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-03 | — | — | US | disclosed |
| CN-119080874-A | O-tert-butyl-L-seryl-glycine and preparation method thereof | 四川什邡市三高生化实业有限公司 | 2024-12-06 | — | — | CN | disclosed |
| CN-118696048-A | Camptothecin derivative, antibody-drug conjugate and pharmaceutical composition based on camptothecin derivative and application of camptothecin derivative | 同宜医药（苏州）有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-113698457-B | Preparation method of gonadorelin acetate | 上海丽珠制药有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-20240140915-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. | 2024-05-02 | — | — | US | disclosed |
| US-20240067612-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| CN-117529476-A | Preparation of substituted 1, 2-diamino heterocyclic derivatives and their use as medicaments | 亚飞络思制药公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-110678198-B | Targeting modules to immune cells expressing universal chimeric antigen receptor and their use in the treatment of cancer, infections and autoimmune disorders | 阿文塞勒欧洲有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20090082254-A1 | Coupling of Polypeptides at the C-Terminus | NOVO NORDISK A/S (DK) | 2009-03-26 | — | — | US | disclosed |
| EP-1986694-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | Novo Nordisk A/S (DK) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008021235-A2 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 2-(QUINOLIN-5-YL)-4,5 DISUBSTITUTED-AZOLE DERIVATIVES | SCHERING CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080045718-A1 | Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives | MERCK SHARP & DOHME CORP. | 2008-02-21 | — | — | US | disclosed |
| WO-2007093594-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK HEALTH CARE AG (DK) | 2007-08-23 | — | — | WO | disclosed |
| US-20070078185-A1 | Methods and compositions for controlling invertebrate pests | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2007-04-05 | — | — | US | disclosed |
| CN-1639155-A | Pyrrolidine oxadiazole- and thiadiazole derivatives | APPLIED RESEARCH SYSTEMS (AN) | 2005-07-13 | — | — | CN | disclosed |
| CN-1308608-A | Substituted beta-amino acid inhibitors of methionine aminopeptidase-2 | ABBOTT LAB (US) | 2001-08-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082254-A1 | Coupling of Polypeptides at the C-Terminus | PTMS, VIP, LNPEP | PPARA 3958/4885GRN 614/4885SORT1 817/4885 |
| US-20070078185-A1 | Methods and compositions for controlling invertebrate pests | DDT, TYR, DDC | PPARA 4676/4885GRN 2323/4885SORT1 2924/4885 |
| US-20240067612-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | PPARA 3369/4885GRN 1053/4885SORT1 4804/4885 |
| US-20240140915-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | PPARA 3369/4885GRN 1053/4885SORT1 4804/4885 |
| US-20080045718-A1 | Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives | PDE4B, PDE4A, PDE3B | PPARA 3223/4885GRN 4678/4885SORT1 4587/4885 |
| US-12565490-B2 | Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease | RIPK1, RIPK4, RIPK2 | PPARA 2222/4885GRN 2380/4885SORT1 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.